In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 4 and 10 as follows:

1. (previously presented)A compound of formula (I):



I

or a pharmaceutically acceptable salt thereof, in which

R^1 and R^2 independently represent phenyl, thienyl or pyridyl each of which is independently optionally substituted by one or more groups represented by Z;

Z represents a C_{1-8}.alkyl group optionally substituted by one or more: hydroxy; a C_{1-6} alkoxy group optionally substituted by one or more fluoro; a C_{3-8} cycloalkyl group; a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur; or by a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6} alkoxycarbonyl group), or Z represents a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (optionally substituted by one or more fluoro), hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethylsulphonyl, nitro, a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6} alkoxycarbonyl group), mono or di C_{1-3} alkylamido, C_{1-3} alkylthio, C_{1-3} alkylsulphonyl, C_{1-3} alkylsulphonyloxy, C_{1-3} alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl, acetyl, an aromatic heterocyclic group which is optionally substituted by one or more halo, C_{1-4} alkyl, trifluoromethyl or trifluoromethoxy, or Z represents a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

R^3 represents a group of formula X-Y-NR^5R^6 in which X is CO or SO_2 and Y is absent or represents NH optionally substituted by a C_{1-3} alkyl group and R^5 and R^6 independently represent: a C_{1-6} alkyl group optionally substituted by one or more hydroxy; an (amino) C_{1-4} alkyl- group in which the amino is optionally substituted by one or more C_{1-3} alkyl groups; a group (C_{3-12} cycloalkyl)$(CH_2)_g$- wherein g is 0, 1, 2 or 3, and wherein the cycloalkyl is optionally substituted by one or more fluoro, hydroxy, C_{1-3} alkyl, C_{1-3} alkoxy, trifluoromethyl or trifluoromethoxy; a group – $(CH_2)_r$(phenyl)$_s$ in which r is 0, 1, 2, 3 or 4, and s is 1 when r is 0, otherwise s is 1 or 2, and the phenyl groups are optionally independently substituted by one or more groups represented by Z; naphthyl; anthracenyl; a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, benzyl or an amino group -NR^xR^y in which R^x and R^y independently represent H or C_{1-4} alkyl; 1-adamantylmethyl; a group -($CH_2)_t$Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted by one or more C_{1-3} alkyl groups and Het represents an aromatic heterocyclic group optionally substituted by one, two or three groups selected from a C_{1-5} alkyl group, a C_{1-5} alkoxy group or halo; or R^5 represents H and R^6 is as defined above; or R^5 and R^6 together with the nitrogen atom to which they are attached represent a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group -NR^xR^y in which R^x and R^y independently represent H or C_{1-4} alkyl;

R^4 represents a group of formula $(CH_2)_nCOOR^7$ in which n is 0, 1, 2, 3 or 4; and R^7 represents a C_{4-12} alkyl group, a C_{3-12} cycloalkyl group or a (C_{3-12} cycloalkyl) C_{1-3} alkyl-group each of which is optionally substituted by one or more of the following: a C_{1-6} alkyl, fluoro, amino or hydroxyl group, or R^7 represents a group – $(CH_2)_a$phenyl in which a is 0, 1, 2, 3 or 4, and the phenyl group is optionally substituted by one or more groups represented by Z which may be the same or different, or R^7 represents a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more of the following: oxygen, sulphur or nitrogen; wherein

the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, C_{1-3} acyl, hydroxy, amino or benzyl groups; or

R^4 represents a group of formula -(CH_2)$_o$-O-(CH_2)$_p$-R^8 in which o and p independently represent an integer 0,1, 2, 3 or 4, and each of the alkyl chains is independently optionally substituted by one or more C_{1-6} alkyl groups, C_{1-6} alkoxy groups or hydroxy and R^8 represents a C_{1-12} alkyl group or a C_{1-12} alkoxy group or R^8 represents phenyl optionally independently substituted by one or more Z groups or R^8 represents an aromatic heterocyclic group or a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more of the following: oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different; with the proviso that R^4 is not a C_{1-3} alkoxymethyl group unless R^3 represents a group of formula X-YNR^5R^6 in which X is CO and Y is absent and R^5 is H and R^6 is a C_{3-8} cycloalkyl group substituted by one or more fluoro or X is CO and Y is NH and NR^5R^6 together represent a piperidino group substituted by one or more fluoro; or R represents a C_{3-8} cycloalkyl group or a C_{3-8} cycloalkenyl group optionally substituted by one or more groups represented by Z which may be the same or different; or

R^4 represents a C_{4-12} alkyl group optionally substituted by one or more fluoro, hydroxy, or amino groups; or

R^4 represents a group of formula -(CH_2)$_q$$R^9$ in which q is 0, 1, 2, 3 or 4, and R^9 represents a C_{3-12} cycloalkyl group, a C_{3-12} cycloalkenyl group, phenyl, an aromatic heterocyclic group or a saturated or partially unsaturated 5-to-8-membered heterocyclic group containing one or more of the following: oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different; or

R^4 represents a group of formula – L^1R^9 in which L^1 represents a C_{2-6} alkenylene chain optionally substituted by one or more C_{1-4} alkyl groups; or

R^4 represents a group of formula -(CH_2)$_m$-O-(CO)-R^{10} in which m represents an integer 0, 1, 2, 3 or 4, in which R^{10} represents a C_{1-12} alkyl group optionally substituted by one or more fluoro, hydroxy, or amino groups or R^{10} represents a group of formula -(CH_2)$_q$$R^9$; or

R^4 represents a group of formula $CONR^{11}R^{12}$ in which R^{11} and R^{12} independently represent H or a C_{1-8} alkyl group or a C_{1-8} alkyl group substituted by one or more hydroxy groups, provided that at least one of R^{11} and R^{12} is a hydroxy C_{1-8} alkyl group; or

R^4 represents a group of formula $-L^2CN$ in which L^2 represents a C_{1-6} alkylene chain.

2. (previously presented) A compound according to claim 1 represented by formula IIa:



IIa

wherein

R^1 and R^2 independently represent phenyl optionally independently substituted by halo or pyridyl,

R^4 represents a C_{4-8} alkyl group, a group CH_2OR^8 in which R^8 is a C_{4-8} alkyl group, or a group CO_2R^7 in which R^7 represents a C_{4-8} alkyl group, and

Y represents NH; and R represents H and R^6 represents perfluorophenyl or phenyl optionally substituted by trifluoromethyl; or R^5 and R^6 together with the nitrogen to which they are attached represent piperidino, morpholino or piperazino, each of which is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

or Y is absent; and R^5 represents H or a C_{1-6} alkyl group optionally substituted by amino and R^6 represents tetrahydropyranyl or 4-piperidinyl optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl or a C_{1-6} alkyl group optionally substituted by amino; or R^5 and R^6 together with the nitrogen to which they are attached represent piperidino, morpholino or piperazino, each of which is optionally substituted by C_{1-3} alkyl or fluoro.

3. (previously presented) A compound according to claim 1 represented by formula IIb:



IIb

wherein

R^1 and R^2 represent phenyl independently optionally substituted by one or more chloro and

R^7 represents butyl, *tert*-butyl, cyclohexyl or benzyl.

4. (currently amended) A compound according to claim 1 represented by formula IIc:



IIc

wherein

R^1 and R^2 represent phenyl independently optionally substituted by one or more chloro or methyl;

u is 0, 1,2, 3, or 4;

R^j represents triazolyl, tetrazolyl, imidazolyl, pyrrolyl, thiazolyl, oxazolyl, oxazinolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, ~~azolactonyl~~ or azetidinyl each of which is optionally substituted by one or more of the following: morpholinyl, piperidinyl, pyrrolidinyl, a C_{1-3} alkylthio group, a C_{3-6} cycloalkyl group, C_{1-3} alkoxy, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6}alkyl)amino, or a C_{1-6} alkyl group optionally substituted by one or more of the following: C_{1-3} alkoxy, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl, or a group of formula $CH(X)R^pR^q$ in which X is hydroxy, a C_{1-6} alkoxy group,

difluoromethoxy, C_{1-6} alkyl, amino, C_{1-6} alkylamino, di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl, R^p represents hydrogen, a C_{1-6}alkyl group or a C_{3-6} cycloalkyl group and R^q represents hydrogen, a C_{1-6}alkyl group or a C_{3-6}cycloalkyl group or R^j represents C_{1-6}alkoxy group terminally substituted on carbon by one or more fluoro; and

R^k represents piperidino, 4,4-difluorocyclohexyl or C_{3-6} alkyl optionally substituted by hydroxy.

5. (previously presented) A compound according to claim 4, in which

R^1 and R^2 represent phenyl independently optionally substituted by one or more chloro or methyl;

R^j represents triazolyl or tetrazolyl each of which is optionally substituted by one or more of the following: a C_{1-3} alkylthio group, a C_{3-6} cycloalkyl group or a C_{1-6} alkyl group optionally substituted by one or more of the following: C_{1-3} alkoxy, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl or pyrrolidinyl, or a group of formula $CH(X)R^pR^q$ in which X is hydroxy, difluoromethoxy, C_{1-6}alkyl, amino C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, morpholinyl, piperidiyl or pyrrolidinyl, R^p represents hydrogen, a C_{1-6}alkyl group or a C_{3-6}cycloalkyl group and R^q represents hydrogen, a C_{1-6}alkyl group or a C_{3-6}cycloalkyl group or R^j represents C_{1-6}alkoxy group terminally substituted on carbon by one or more fluoro; and u is 0 or 1; and

R^k represents piperidino, 4,4-difluorocyclohexyl or C_{3-6} alkyl optionally substituted by hydroxy.

6. (previously presented) A compound selected from:

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

butyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

cyclohexyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

benzyl 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-({[cis-2-hydroxycyclohexyl]amino}carbonyl)-pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-({[trans-2-hydroxycyclohexyl]amino}carbonyl)-pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-({2-[4-(trifluoromethyl)phenyl]hydrazino}carbonyl)-pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(morpholin-4-ylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-({2-[4-(tert-butylhydrazino}carbonyl)pyrazine-2-carboxylate;

3-(tert-butoxymethyl)-5,6-bis(4-chlorophenyl)-N-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(cyclohexylidenemethyl)-N-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(cyanomethyl)-N-piperidin-1 -ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(1-methoxyethyl)-*N*-piperidin-l-ylpyrazine-2-carboxamide;

tert-butyl 5,6-bis(4-chlorophenyl)-3-{[(2-hydroxy-l-methylethyl)amino]carbonyl}-pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-{[(4,4-difluorocyclohexyl)amino]carbonyl}pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-[(pentylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-{[(l-ethylpropyl)amino]carbonyl} pyrazine-2-carboxylate;

tert-butyl 5,6-bis(4-chlorophenyl)-3-{[(4,4-difluoropiperidin-l-yl)ammo]carbonyl}-pyrazine-2-carboxylate;

5,6-bis(4-chlorophenyl)-N-piperidin-l-yl-3-[(4-propyl-1H-l,2,3-triazol-l-yl)methyl]pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-{[4-(1 -hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-{[5-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-N-piperidin-1-ylpyrazine-2-carboxamide;

tert-butyl {[1-({5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]methyl}carbamate;

tert-butyl {[1 -({5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazin-2-yl} methyl)-1H-1,2,3-triazol-5-yl]methyl}carbamate;

3-{[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl}-5,6-bis(4-chlorophenyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

3-{[5-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl}-5,6-bis(4-chlorophenyl)-N-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(phenoxymethyl)-*N*'-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(morpholin-4-ylmethyl)-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-(piperidin-1-ylmethyl)-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(cyclohex-2-en-1-yloxy)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(cyclohexyloxy)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(2-hydroxyethyl)-*N*'-piperidin-1-ylpyrazine-2,3 -dicarboxamide;

5,6-bis(4-chlorophenyl)-*N*-(3-hydroxybutyl)-*N*'-piperidin-1-ylpyrazine-2,3 -dicarboxamide;

5,6-bis(4-chlorophenyl)-*N*-(3-hydroxypropyl)-*N*'-piperidin-1-ylpyrazine-2,3 -dicarboxamide;

Tert-butyl 5,6-bis(4-methylphenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylate;

5,6-bis(4-methylphenyl)-*N*-piperidin-1-yl-3-(1*H*-tetrazol-1-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-methylphenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-l-yl-3-(1*H*-tetrazol-l-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluoropiperidm-l-yl)-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(2-methoxyethoxy)methyl]-*N*-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-cyclopropyl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-cyclopropyl- 1*H*-tetrazol-1-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-methyl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-methyl-l*H*-tetrazol-l-yl)methyl]-*N*'-piperidin-l-ylpyrazine-2-carboxamide;

tert-butyl 6-(4-chlorophenyl)-5-(4-methylphenyl)-3-[(piperidin-l-ylamino)carbonyl]pyrazine-2-carboxylate;

tert-butyl 5-(4-chlorophenyl)-6-(4-methylphenyl)-3-[(piperidin-l-ylamino)carbonyl]pyrazine-2-carboxylate;

6-(4-chlorophenyl)-5-(4-methylphenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

5-(4-chlorophenyl)-6-(4-methyrphenyl)-*N*-piperidin-1-yl-3-(2*H*-tetrazol-2-ylmethyl)pyrazine-2-carboxamide;

tert-butyl 5,6-bis(4-chlorophenyl)-3-{[(2-hydroxyethyl)(methyl)amino]-carbonyl}pyrazine-2-carboxylate;

5,6-bis-(4-chloro-phenyl)-3-propoxy-pyrazine-2-carboxylic acid piperidin-1-ylamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-l-yl-3-(2*H*-tetrazol-5-ylmethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-l-yl-3-(l*H*-tetrazol-5-yl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-morpholin-4-yl-2*H*-tetrazol-2-yl)methyl]-*N*-piperidin-l-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(5-morpholin-4-yl-1*H*-tetrazol-1-yl)methyl]-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-l-yl-3-[(5-pyrrolidin-l-yl-2*H*-tetrazol-2-yl)methyl]pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-piperidin-1-yl-3-[(5-pyrrolidin-1-yl-l*H*-tetrazol-1-yl)methyl]pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-{[5-(methylthio)-2*H*-tetrazol-2-yl]methyl}-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-{[5-(methylthio)-1*H*-tetrazol-1-yl]methyl}-*N*-piperidin-1-ylpyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-(methoxymethyl)pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-{[(4-fluorobenzyl)oxy]methyl}pyrazine-2-carboxamide;

5,6-bis(4-chlorophenyl)-3-[(4,4-difluoropiperidin-l-yl)methyl]-*N*-piperidine-l-ylpyrazine-2-carboxamide;

5,6-bis(4-ch.lorophenyl)-*N*-(4,4-difluorocyclohexyl)-3-[(4,4-difluoropiperidin-l-yl)methyl]pyrazine-2-carboxamide; or

5,6-bis(4-chlorophenyl)-*N*-(4,4-difluoropiperidin-l-yl)-3-(methoxymethyl)pyrazine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

7. (cancelled).

8. (previously presented) A pharmaceutical formulation comprising a compound of any one of claims 1-4 or 6 and a pharmaceutically acceptable adjuvant, diluent or carrier.

9. (cancelled).

10. (currently amended) A method of treating obesity, ~~psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia,~~ bulimia, ~~attention disorders, epilepsy, and related conditions, neurological disorders, neurological disorders , Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease , immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal system, and~~ extended abuse, addiction and/or relapse indications, comprising administering a pharmacologically effective amount of a compound of claim 1 to a patient in need thereof.

11. (previously presented) A method for the treatment of obesity comprising administering a pharmacologically effective amount of a compound of any one of claims 1-4 or 6 to a patient in need thereof.

12. (previously presented) A composition comprising a compound of claim 1 or 6 in combination with another pharmaceutically active compound.

13. (previously presented) A process for the preparation of a compound of claim 1 comprising:

a) reacting a compound of formula III;



III

with an amine of formula IV:

$$R^5R^6YNH_2 \quad (IV)$$

or a salt thereof, in a solvent, in the presence of a coupling agent and optionally in the presence of a base at a temperature in the range of -25°C to 150°C to provide a compound of claim 1 in which R^3 is $COYNR^5R^6$, or

b) reacting a compound of formula XI:



XI

with a compound of formula XII:



XII

in an inert solvent and optionally in the presence of a catalyst at a temperature in the range of -25°C to 150°C to provide a compound of claim 1 in which R^4 represents a group CH_2(1H-1,2,3-triazol-1-yl) in which the triazole is optionally substituted on carbon by Z; or

c) reacting a compound of formula XIV:



XIV

in which R^c represents an alkyl group, with an amine of formula IV:

$R^5R^6YNH_2$ (IV)

or a salt thereof, in a solvent in the presence of a coupling agent and optionally in an inert atmosphere at a temperature in the range of -25 °C to 150°C to provide a compound of claim 1 in which R^3 is $COYNR^5R^6$; or

d) reacting a compound of formula XV:



XV

in which X represents a leaving group, with an amine of formula IV:

$R^5R^6YNH_2$ (IV)

or a salt thereof, in a solvent optionally in the presence of a base at a temperature in the range of -25°C to 150°C to provide a compound of claim 1 in which R^3 is $COYNR^5R^6$; or

e) de-protecting a compound of claim 1, in which one or more groups is protected, to provide a compound of claim 1.

14. (previously presented) A compound of formula XI:



XI

in which R^1 and R^2 independently represent phenyl, thienyl or pyridyl each of which is independently optionally substituted by one or more groups represented by Z;

Z represents a C_{1-8} alkyl group optionally substituted by one or more: hydroxy; a C_{1-6} alkoxy group optionally substituted by one or more fluoro: a C_{3-8} cycloalkyl group; a saturated or partially unsaturated 5- to 8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur; or by a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6}

alkoxycarbonyl group), or Z represents a C_{3-8} cycloalkyl group, a C_{1-6} alkoxy group (optionally substituted by one or more fluoro), hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethylsulphonyl, nitro, a group $NR^{10}R^{11}$ (in which R^{10} and R^{11} independently represent hydrogen, a C_{1-6} alkyl group, a C_{1-6} alkanoyl group or a C_{1-6} alkoxycarbonyl group), mono or di C_{1-3} alkylamido, C_{1-3} alkylthio, C_{1-3} alkylsulphonyl, C_{1-3} alkylsulphonyloxy, C_{1-3} alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl, acetyl, an aromatic heterocyclic group which is optionally substituted by one or more halo, C_{1-4} alkyl, trifluoromethyl or trifluoromethoxy, or Z represents a saturated or partially unsaturated 5-to 8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

R^3 represents a group of formula $X\text{-}Y\text{-}NR^5R^6$ in which X is CO or SO_2 and Y is absent or represents NH optionally substituted by a C_{1-3} alkyl group and R^5 and R^6 independently represent: a C_{1-6} alkyl group optionally substituted by one or more hydroxy; an (amino) C_{1-4} alkyl-group in which the amino is optionally substituted by one or more C_{1-3} alkyl groups; a group (C_{3-12} cycloalkyl$(CH_2)_g$- wherein g is 0,1,2, or 3, and wherein the cycloalkyl is optionally substituted by one or more fluoro, hydroxy, C_{1-3} alkyl, C_{1-3} alkoxy, trifluoromethyl or trifluoromethoxy; a group $-(CH_2)_r(phenyl)_s$ in which r is 0, 1, 2, 3 or 4, and s is 1 when r is 0, otherwise s is 1 or 2, and the phenyl groups are optionally independently substituted by one or more groups represented by Z; naphthyl; anthracenyl; a saturated or partially unsaturated 5- to 8-membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl; 1-adamantylmethyl; a group $-(CH_2)_tHet$ in which t is 0, 1, 2, 3, or 4, and the alkylene chain is optionally substituted by one or more C_{1-3} alkyl groups and Het represents an aromatic heterocyclic group optionally substituted by one, two or three groups selected from a C_{1-5} alkyl group, a C_{1-5} alkoxy group or halo; or R^5 represents H and R^6 is as defined above; or R^5 and R^6 together with the nitrogen atom to which they are attached represent a saturated or partially

unsaturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl, hydroxy, fluoro, trifluoromethyl, trifluoromethoxy, benzyl, C_{1-6} alkanoyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl.